PTHS (Pelthos Therapeutics) Accounts Payable: $6.15 Mil (As of Mar. 2026)


PTHS Pelthos Therapeutics Inc PTHS
8 GF Score
Price $25.77
! 4 Warning Signs
View Full Analysis

What is Pelthos Therapeutics Accounts Payable?

Pelthos Therapeutics PTHS -7.96% 8 Accounts Payable is $6.15 Mil as of Mar. 2026. GuruFocus rates PTHS with a GF Score™ of 8/100. The stock has 4 warning signs investors should review.

Pelthos Therapeutics's Accounts Payable for the quarter that ended in Mar. 2026 was $6.15 Mil.

Pelthos Therapeutics's quarterly Accounts Payable declined from Sep. 2025 ($5.67 Mil) to Dec. 2025 ($2.99 Mil) but then increased from Dec. 2025 ($2.99 Mil) to Mar. 2026 ($6.15 Mil).

Pelthos Therapeutics's annual Accounts Payable declined from Dec. 2023 ($4.62 Mil) to Dec. 2024 ($1.90 Mil) but then increased from Dec. 2024 ($1.90 Mil) to Dec. 2025 ($2.99 Mil).

Pelthos Therapeutics Accounts Payable Related Terms

Pelthos Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Pelthos Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pelthos Therapeutics Accounts Payable Chart

Pelthos Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial 2.58 2.99 4.62 1.90 2.99

Pelthos Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.60 4.99 5.67 2.99 6.15
PTHS
8GF Score
Pelthos Therapeutics Inc PTHS
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pelthos Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $6.15 Mil mean?
Pelthos Therapeutics (PTHS) has a Accounts Payable of $6.15 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Pelthos Therapeutics and its competitors.
Is Pelthos Therapeutics' Accounts Payable too high?
Pelthos Therapeutics' current Accounts Payable is $6.15 Mil. Overall, Pelthos Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Pelthos Therapeutics' Accounts Payable compare to CGTX and BDTX?
Pelthos Therapeutics' Accounts Payable of $6.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Pelthos Therapeutics and its competitors. Pelthos Therapeutics's current Accounts Payable is $6.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pelthos Therapeutics stock overvalued right now?
Pelthos Therapeutics (PTHS) has a current Accounts Payable of $6.15 Mil. The current Accounts Payable is $6.15 Mil. Pelthos Therapeutics' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Pelthos Therapeutics (PTHS), the current Accounts Payable is $6.15 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pelthos Therapeutics Business Description

Address 4020 Stirrup Creek Drive, Suite 110, Durham, NC, USA, 27703
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
8GF Score

Get the complete analysis for PTHS

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.77
Price